The EWMA Patient Outcome Group has a clinical scientific platform, including both clinicians and representatives from companies working within wound healing.
Discussions and objectives of the group touch upon topics such as structure of treatment as well as more traditional clinical trials and approval and reimbursement of wound care products.
Meetings
The group will meet 2-3 times a year.
For more information about the EWMA Patient Outcome Group please contact EWMA Business Office at ewma@ewma.org
Primary objectives of the group are to:
- Identify barriers:
- With a starting point in the current debate on evidence in wound healing and the Cochrane levels of evidence, the group will define the primary barriers (as experienced by clinicians and companies) related to creating and implementation of evidence based guidelines in wound healing.
- Propose guidelines for clinical data collection:
- The objective will be to define how existing guidelines for clinical trials (e.g. RCTs or more “practical” studies (real life studies etc.)) can be adapted to wound management, e.g. by including other end points such as number of dressing changes, health economics, QOL, education of staff and structure of treatment.
- Participate in the public debate / policy making:
- The working group should present a common viewpoint on clinical trials of wound management products in relation to the debate on both national and European level. A primary goal will be to influence the decision making processes concerning approval and reimbursement of wound management products. EWMA will act as shareholder and work to influence the national agendas in order to put chronic wounds on the agenda.
- A central European HTA unit is assumed to be established. The working group should approach involved institutions in order to present the work and conclusions of the group in relation to evidence in HTA of wound management products.
- Create and implement consensus:
- Other interested parties (clinicians, companies, reimbursement authorities, European collaborative groups and institutions) should be involved in order to create consensus within the area. A pan European consensus with a national implementation strategy has been proposed.
Members
Clinicians/Individual
Finn Gottrup (Chair)
Jan Apelqvist
Luc Gryson
Zena Moore
Patricia Price
Hugo Partsch
John Posnett
Industry representatives from
BBraun
Coloplast
ConvaTec
Covidien
KCI
Lohmann & Raucher
Paul Hartmann AG
Mölnlycke Healthcare
|
